Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

heritage pharmaceuticals inc. - moexipril hydrochloride (unii: q1umg3uh45) (moexiprilat - unii:h3753190js), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - moexipril hydrochloride 7.5 mg - moexipril hydrochloride and hydrochlorothiazide tablets are indicated for treatment of patients with hypertension. this fixed combination is not indicated for the initial therapy of hypertension ( see dosage and administration). in using moexipril hydrochloride and hydrochlorothiazide tablets, consideration should be given to the fact that another ace inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that moexipril hydrochloride and hydrochlorothiazide tablets does not have a similar risk (see warnings, neutropenia/agranulocytosis ). in addition, ace inhibitors, for which adequate data are available, cause a higher rate of angioedema in black than in nonblack patients (see warnings, angioedema ). moexipril hydrochloride and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

rising pharma holdings, inc. - cevimeline hydrochloride (unii: p81q6v85np) (cevimeline - unii:k9v0cdq56e) - cevimeline hydrochloride anhydrous 30 mg - cevimeline is indicated for the treatment of symptoms of dry mouth in patients with sjögren’s syndrome. cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to cevimeline, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

actavis pharma, inc. - trientine hydrochloride (unii: hc3nx54582) (trientine - unii:sj76y07h5f) - trientine hydrochloride 250 mg - trientine hydrochloride is indicated in the treatment of patients with wilson's disease who are intolerant of penicillamine. clinical experience with trientine hydrochloride is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. trientine hydrochloride and penicillamine cannot be considered interchangeable. trientine hydrochloride should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. unlike penicillamine, trientine hydrochloride is not recommended in cystinuria or rheumatoid arthritis. the absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. in 15 patients with rheumatoid arthritis, trientine hydrochloride was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. trientine hydrochloride is not indicated f

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

oceanside pharmaceutials - trientine hydrochloride (unii: hc3nx54582) (trientine - unii:sj76y07h5f) - trientine hydrochloride 250 mg - trientine hydrochloride capsules are indicated in the treatment of patients with wilson’s disease who are intolerant of penicillamine. clinical experience with trientine hydrochloride capsules is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient’s dose have not been well defined. trientine hydrochloride capsules and penicillamine cannot be considered interchangeable. trientine hydrochloride capsules should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. unlike penicillamine, trientine hydrochloride capsules are not recommended in cystinuria or rheumatoid arthritis. the absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. in 15 patients with rheumatoid arthritis, trientine hydrochloride capsules were reported not to be effective in improving any clinical or biochemical parameter after 12 weeks

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

remedyrepack inc. - ziprasidone hydrochloride (unii: 216x081oru) (ziprasidone - unii:6uka5vej6x) - ziprasidone hydrochloride capsule is an atypical antipsychotic. in choosing among treatments, prescribers should be aware of the capacity of ziprasidone hydrochloride capsule to prolong the qt interval and may consider the use of other drugs first (5.2) ziprasidone hydrochloride capsule is indicated as an oral formulation for the treatment of schizophrenia. (1.1) adults: efficacy was established in 4 to 6 week trials and one maintenance trial in adult patients with schizophrenia  (14.1) because of ziprasidone's dose-related prolongation of the qt interval and the known association of fatal arrhythmias with qt prolongation by some other drugs, ziprasidone is contraindicated: - in patients with a known history of qt prolongation (including congenital long qt syndrome) - in patients with recent acute myocardial infarction - in patients with uncompensated heart failure pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the qt interval have not been performed. an additive eff

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - trientine hydrochloride (unii: hc3nx54582) (trientine - unii:sj76y07h5f) - trientine hydrochloride capsules are indicated in the treatment of patients with wilson’s disease who are intolerant of penicillamine. clinical experience with trientine hydrochloride capsules are limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient’s dose have not been well defined. trientine hydrochloride capsules and penicillamine cannot be considered interchangeable. trientine hydrochloride capsules should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. unlike penicillamine, trientine hydrochloride capsules are not recommended in cystinuria or rheumatoid arthritis. the absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. in 15 patients with rheumatoid arthritis, trientine hydrochloride was reported not to be effective in improving any clinical or biochemical parameter after 12

Σαουδική Αραβία - Αγγλικά - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

fresenius kabi norge as, norway - chromic chloride,copper chloride,ferric chloride,manganese chloride tetrahydrate,potassium iodide,sodium fluoride,sodium molybdate,sodium selenite anhydrous,zinc chloride - concentrate for solution for infusion - 5.33,0.10,0.54,19.8,16.6,0.21,4.85,17.3,17.3 µ/ml, µg,

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - ferric chloride hexahydrate ; zinc chloride ; manganese chloride tetrahydrate ; cupric chloride dihydrate ; potassium iodide ; chromium trichloride hexahydrate; sodium selenite ; sodium molybdate dihydrate ; sodium fluoride - concentrate for soln for inf - 10 millilitre - electrolytes in combination with other drugs

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - ferric chloride hexahydrate; zinc chloride; manganese chloride tetrahydrate; copper chloride dihydrate; chromium trichloride hexahydrate; sodium selenite anhydrous; sodium molybdate dihydrate; sodium fluoride; potassium iodide - concentrate for solution for infusion - 10 millilitre(s) - electrolyte solutions; electrolytes in combination with other drugs

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

physicians total care, inc. - anagrelide hydrochloride (unii: vns4435g39) (anagrelide - unii:k9x45x0051) - anagrelide 0.5 mg - anagrelide hydrochloride capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events (see clinical studies , dosage and administration ). anagrelide is contraindicated in patients with severe hepatic impairment. exposure to anagrelide is increased 8 fold in patients with moderate hepatic impairment (see clinical pharmacology ). use of anagrelide in patients with severe hepatic impairment has not been studied (see also warnings, hepatic ).